The Cairn Podcast: Marking the Trail for Veterinarians

Rapamycin use in cats with subclinical hypertrophic cardiomyopathy

Magdalena Grudzinski-Hall Season 1 Episode 29

Join us for this exciting discussion as we welcome Dr. Joshua Stern, DVM, PhD, DACVIM (Cardiology) to discuss results of the recently completed RAPACAT trial, evaluating the effects of delayed release rapamycin on left ventricular wall thickness in cats with hypertrophic cardiomyopathy (HCM). Dr. Stern is the Associate Dean for Research & Graduate Studies and Professor of Cardiology at North Carolina State University School of Veterinary Medicine. He is a global leader in the field of veterinary cardiology genetics, with well over 100 publications to date. Following the success of the RAPACAT trial, Dr. Stern and Trivium Vet are organizing a large multicenter study (the HALT HCM study), for which registration is now open (see link below). We also review the etiology and natural history of HCM in cats, rapamycin's effects on mTOR, additional emerging therapies for treating HCM in cats, and other potential uses of rapamycin in veterinary cardiology. 

Episode resources

Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial

The HALT HCM Study information and registration

Trivium Vet

People on this episode